促性腺激素释放激素激动剂类似物（ICI 118630）对人睾丸体内及体外内分泌功能的影响。
Effects of a gonadotropin-releasing hormone agonist analog (ICI 118630) on endocrine functions of human testis in vivo and in vitro.
作者信息
Namiki M, Nonomura N, Nakamura M, Okuyama A, Sonoda T, Nishimune Y, Matsumoto K
机构信息
Department of Urology, Osaka University Medical School, Japan.
出版信息
Fertil Steril. 1987 Dec;48(6):1012-7. doi: 10.1016/s0015-0282(16)59601-0.
Six prostatic cancer patients were treated with a gonadotropin-releasing hormone agonist analog (ICI 118630, ICI Pharmaceutical Division, Macclesfield, England) for 4 weeks, and serum testosterone (T) had fallen to the castration level in all patients. Subsequently, three of the patients were orchiectomized. There were no significant differences in follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hCG) receptors between the testes treated with ICI 118630 and testes obtained from untreated prostatic cancer patients. In the other three patients, testicular responsiveness evaluated using hCG stimulation was similar before and after 4 weeks of treatment. In vitro studies testes removed from untreated prostatic cancer patients were cultured in a medium with or without ICI 118630 for 5 days. There were no significant differences in FSH and hCG receptors and T production between the two groups. In conclusion, ICI 118630 had no direct inhibitory effect on human testes.
六名前列腺癌患者接受促性腺激素释放激素激动剂类似物（ICI 118630，英国麦克尔斯菲尔德 ICI 制药部）治疗 4 周，所有患者血清睾酮（T）均降至去势水平。随后，其中三名患者接受了睾丸切除术。接受 ICI 118630 治疗的睾丸与从未经治疗的前列腺癌患者获取的睾丸之间，促卵泡激素（FSH）和人绒毛膜促性腺激素（hCG）受体无显著差异。在另外三名患者中，使用 hCG 刺激评估的睾丸反应性在治疗 4 周前后相似。体外研究中，从未经治疗的前列腺癌患者切除的睾丸在含或不含 ICI 118630 的培养基中培养 5 天。两组之间 FSH 和 hCG 受体以及 T 生成无显著差异。总之，ICI 118630 对人体睾丸无直接抑制作用。
Zotero 插件